Volunteer for Clinical Studies
Healthy volunteers help NIAID to evaluate treatment and prevention options for a wide range of diseases and conditions in our mission areas. Help us to improve human health.
The New Strategic Vision for NIAID
NIAID’s strategic aims are to address the most impactful infectious diseases that Americans currently face with evidence from gold standard science; and to support innovative research to address fundamental studies in immunology and allergic and autoimmune diseases to improve patient outcomes.
NIAID Approach to the NIH Unified Funding Strategy
NIAID has a new, standardized process for assessing grant applications. The process considers scientific merit, public health impact, investigator-specific factors, research gaps, and alignment with HHS, NIH, and NIAID priorities. This approach complements NIH peer review to guide funding selections.
NIAID Discovery Leads to Novel Probiotic for Eczema
NIAID researchers discovered that the bacteria, Roseomonas mucosa which occurs naturally as part of the typical microbiome present on healthy skin, can safely relieve eczema symptoms in adults and children. This discovery led to the availability of a topical eczema probiotic.
Acting Director Jeffery Taubenberger, M.D., Ph.D.
Jeffery K. Taubenberger, M.D., Ph.D.
Dr. Taubenberger was named the Acting Director of NIAID in April 2025. He oversees a $6.6 billion budget that supports research to advance the understanding, diagnosis, treatment and prevention of infectious, immunologic, and allergic diseases. He is known for sequencing, reconstruction, and characterization of the virus responsible for the 1918 influenza pandemic.
Learn more about Dr. Taubenberger
